Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1993 Jan;52(1):58–60. doi: 10.1136/ard.52.1.58

Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugs.

A Crilly 1, R Madhok 1, J Watson 1, H A Capell 1
PMCID: PMC1004957  PMID: 8093995

Abstract

Serum soluble interleukin 2 receptor (sIL-2R) concentrations reflect lymphocyte activation in vivo. An investigation was carried out to determine if sIL-2R concentrations correlate with existing disease activity parameters in patients with rheumatoid arthritis (RA) and whether these concentrations are modulated by treatment with second line drugs. Seventy nine patients with rheumatoid arthritis with active disease were prospectively treated with sodium aurothiomalate, auranofin, or sulphasalazine. Sequential concentrations of sIL-2R were measured by enzyme linked immunosorbent assay (ELISA). No correlations were observed between sIL-2R concentrations and clinical parameters and there were only moderate associations with concentrations of C reactive protein and the erythrocyte sedimentation rate. Concentrations of sIL-2R did not significantly change with treatment. It is concluded that sIL-2R probably measures an aspect of rheumatoid synovitis distinct from acute phase reactants and is not influenced by treatment with second line drugs.

Full text

PDF
58

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Emery P., Wood N., Gentry K., Stockman A., Mackay I. R., Bernard O. High-affinity interleukin-2 receptors on blood lymphocytes are decreased during active rheumatoid arthritis. Arthritis Rheum. 1988 Sep;31(9):1176–1181. doi: 10.1002/art.1780310914. [DOI] [PubMed] [Google Scholar]
  3. Keystone E. C., Snow K. M., Bombardier C., Chang C. H., Nelson D. L., Rubin L. A. Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum. 1988 Jul;31(7):844–849. doi: 10.1002/art.1780310704. [DOI] [PubMed] [Google Scholar]
  4. Kurosaka M., Ziff M. Immunoelectron microscopic study of the distribution of T cell subsets in rheumatoid synovium. J Exp Med. 1983 Oct 1;158(4):1191–1210. doi: 10.1084/jem.158.4.1191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Matsubara T., Ziff M. Inhibition of human endothelial cell proliferation by gold compounds. J Clin Invest. 1987 May;79(5):1440–1446. doi: 10.1172/JCI112972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Möttönen T. T., Hannonen P., Toivanen J., Rekonen A., Oka M. Value of joint scintigraphy in the prediction of erosiveness in early rheumatoid arthritis. Ann Rheum Dis. 1988 Mar;47(3):183–189. doi: 10.1136/ard.47.3.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Paulus H. E. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum. 1990 Jan;33(1):113–120. doi: 10.1002/art.1780330116. [DOI] [PubMed] [Google Scholar]
  8. Porter D., Madhok R., Hunter J. A., Capell H. A. Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis. Ann Rheum Dis. 1992 Apr;51(4):461–464. doi: 10.1136/ard.51.4.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rooney M., Whelan A., Feighery C., Bresnihan B. Changes in lymphocyte infiltration of the synovial membrane and the clinical course of rheumatoid arthritis. Arthritis Rheum. 1989 Apr;32(4):361–369. doi: 10.1002/anr.1780320402. [DOI] [PubMed] [Google Scholar]
  10. Rubin L. A., Nelson D. L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990 Oct 15;113(8):619–627. doi: 10.7326/0003-4819-113-8-619. [DOI] [PubMed] [Google Scholar]
  11. Smith K. A. Interleukin-2: inception, impact, and implications. Science. 1988 May 27;240(4856):1169–1176. doi: 10.1126/science.3131876. [DOI] [PubMed] [Google Scholar]
  12. Soden M., Rooney M., Cullen A., Whelan A., Feighery C., Bresnihan B. Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis. Br J Rheumatol. 1989 Aug;28(4):287–292. doi: 10.1093/rheumatology/28.4.287. [DOI] [PubMed] [Google Scholar]
  13. Wood N. C., Symons J. A., Duff G. W. Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun. 1988 Aug;1(4):353–361. doi: 10.1016/0896-8411(88)90005-4. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES